PI3K inhibitors in the treatment of lymphoma： present and challenges

doi:10.3760/cma.j.cn371439-20240407-00111

Abstract

Abstract:

Abnormal activation of phosphoinositide 3-kinase （PI3K） pathway is one of the pathogenesis of malignant lymphoma. PI3K inhibitors are new targets for lymphoma treatment in recent years. At present， a variety of different types of PI3K inhibitors have been developed， some of which have been approved for clinical use， and some are still in clinical trials. PI3K inhibitors have multiple side effects. Improving safety and efficacy is an important direction for the future development of PI3K inhibitors.

Key words: Phosphatidylinositol 3-kinases, Lymphoma, Drug-related side effects and adverse reactions, Inhibitors

Fu Ying, Wang Huaqing. PI3K inhibitors in the treatment of lymphoma： present and challenges[J]. Journal of International Oncology, 2024, 51(10): 660-666.

Figures/Tables 1

药品名称	研发公司	注册号	注册题目	适应证	靶点	开始日期
INCB-040093^[32]	美国Incyte公司	NCT01905813	A phase 1， open-label， dose escalation， safety and tolerability study of INCB-040093 in subjects with previously treated B-cell malignancies	B细胞恶性肿瘤	PI3Kδ	2013/6/30
parsaclisib^[33]	美国Incyte公司	NCT03126019	A phase 2， multicenter， open-label study of INCB050465， a PI3Kδ inhibitor in relapsed or refractory follicular lymphoma (CITADEL-203)	复发或难治性FL	PI3Kδ	2017/4/24
SHC014748^[34]	南京圣和药业股份有限公司	CTR20180988	SHC014748M在惰性B细胞恶性血液肿瘤患者中的Ⅰ期临床研究	复发或难治性惰性 B细胞恶性血液肿瘤	PI3Kδ	2018/7/2
IOA-244^[35]	瑞士iOnctura 公司	NCT04328844	First-in-human dose study of IOA-244 alone and in combination with pemetrexed/cisplatin in patients with advanced or metastatic cancers	成人非霍奇金淋巴瘤	PI3Kδ	2020/2/25
TQ-B3525^[36]	正大天晴药业集团股份有限公司	CTR20200426	TQ-B3525治疗FL临床试验	复发或难治性FL	PI3Kγ/ PI3Kδ	2020/3/23
HMPL-689^[37]	上海和黄药业有限公司	CTR20210264	HMPL-689治疗复发/难治MZL和FL的临床研究	复发/难治性MZL和FL	PI3Kγ/ PI3Kδ	2021/2/18
linperlisib （YY- 20394）230^[38]	上海璎黎药业有限公司	CTR20210333	YY-20394在复发和（或）难治性外周T/NK细胞淋巴瘤患者中的Ⅱ期临床试验	复发和（或）外周难治性 T/NK细胞淋巴瘤	PI3Kδ	2021/3/12
BGB-10188^[39]	百济神州（北京）生物科技有限公司	CTR20220463	一项BGB-10188（一种PI3Kδ抑制剂）联合泽布替尼治疗成熟B细胞恶性肿瘤患者以及联合替雷利珠单抗治疗实体瘤患者的剂量递增和扩展1/2期研究	CLL、SLL、FL、MZL、套细胞淋巴瘤、弥漫性大B细胞淋巴瘤、晚期实体瘤、非小细胞肺癌、小细胞肺癌、转移性黑素瘤	PI3Kδ	2022/3/14

References 53

[1]	李瑛珏, 路丹. PI3K通路在肿瘤免疫微环境中的作用机制[J]. 国际肿瘤学杂志, 2022, 49(11): 677-680. DOI: 10.3760/cma.j.cn371439-20220612-00133.
[2]	乔薇, 宋腾, 陈馨蕊, 等. PI3K信号通路过度激活对非霍奇金淋巴瘤患者预后的影响及其靶向药物疗效[J]. 国际肿瘤学杂志, 2021, 48(2): 121-124. DOI: 10.3760/cma.j.cn371439-20200615-00024.
[3]	Miller MS, Thompson PE, Gabelli SB. Structural determinants of isoform selectivity in PI3K inhibitors[J]. Biomolecules, 2019, 9(3): 82. DOI: 10.3390/biom9030082.
[4]	Van der Veen L, Schmitt M, Deken MA, et al. Non-clinical toxicology evaluation of the novel non-ATP competitive oral PI3 kinase delta inhibitor roginolisib[J]. Int J Toxicol, 2023, 42(6): 515-534. DOI: 10.1177/10915818231200419.
[5]	Bou Zeid N, Yazbeck V. PI3K inhibitors in NHL and CLL: an unfulfilled promise[J]. Blood Lymphat Cancer, 2023, 8(13): 1-12. DOI: 10.2147/BLCTT.S309171.
[6]	Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase Ⅲ study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia[J]. J Clin Oncol, 2019, 37(16): 1391-1402. DOI: 10.1200/JCO.18.01460. pmid: 30995176
[7]	Isidori A, Loscocco F, Visani G, et al. Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients[J]. Br J Haematol, 2022, 199(3): 339-343. DOI: 10.1111/bjh.18426.
[8]	U.S. Food and Drug Administration. These highlights do not include all the information needed to use ZYDELIG safely and effectively[EB/OL]. [2024-04-01]. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1.
[9]	Kumar A, Bhatia R, Chawla P, et al. Copanlisib: novel PI3K inhibitor for the treatment of lymphoma[J]. Anticancer Agents Med Chem, 2020, 20(10): 1158-1172. DOI: 10.2174/1871520620666200317105207.
[10]	U.S. FOOD and Drug Administration. FDA grants accelerated approval to copanlisib for relapsed follicular lymphoma[EB/OL]. (2017-09-14)[2024-06-11]. https://www.esmo.org/oncology-news/archive/fda-grants-accelerated-approval-to-copanlisib-for-relapsed-follicular-lymphoma.
[11]	Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study[J]. Am J Hematol, 2020, 95(4): 362-371. DOI: 10.1002/ajh.25711.
[12]	Matasar MJ, Capra M, Özcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, ran-domised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(5): 678-689. DOI: 10.1016/S1470-2045(21)00145-5.
[13]	U.S. Food and Drug Administration. Withdrawn \| Cancer accelerated approvals[EB/OL]. (2024-06-06)[2024-06-11]. https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals.
[14]	国家食品药品监督管理局. 2023年05月23日药品批准证明文件送达信息发布[EB/OL]. (2023-05-23)[2024-06-11]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230523155059194.html?type=pc.
[15]	Zou L, Qi Y, Tang L, et al. Clinical review considerations of class Ⅰ PI3K inhibitors in hematolymphatic malignancies by center for drug evaluation[J]. Chin J Cancer Res, 2022, 34(4): 415-421. DOI: 10.21147/j.issn.1000-9604.2022.04.09.
[16]	Frustaci AM, Tedeschi A, Deodato M, et al. Duvelisib for the treatment of chronic lymphocytic leukemia[J]. Expert Opin Pharmacother, 2020, 21(11): 1299-1309. DOI: 10.1080/14656566.2020.1751123. pmid: 32292084
[17]	U.S. Food and Drug Administration. Duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)[EB/OL]. (2018-09-24)[2024-03-30]. https://www.fda.gov/drugs/resources-information-approved-drugs/duvelisib-copiktra-verastem-inc-adult-patients-relapsed-or-refractory-chronic-lympho-cytic-leukemia?elqTrackId=af90d9a841eb4460a1049510b7a4b8e1&elq=bd9e34cfd63648449d74f893955d1922&elqaid=5216&elqat=1&elqCampaignId=4172.
[18]	Wang ZW, Zhou H, Xu J, et al. Safety and efficacy of dual PI3K-δ, γinhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: a systematic review and meta-analysis of prospective clinical trials[J]. Front Immunol, 2022, 13: 1070660. DOI: 10.3389/fimmu.2022.1070660.
[19]	U.S. Food and Drug Administration. FDA warns about possible increased risk of death and serious side effects with cancer drug copiktra (duvelisib)[EB/OL]. (2022-07-14)[2024-03-30]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-possible-increased-risk-death-and-serious-side-effects-cancer-drug-copiktra.
[20]	Davids MS, Kuss BJ, Hillmen P, et al. Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study[J]. Clin Cancer Res, 2020, 26(9): 2096-2103. DOI: 10.1158/1078-0432.CCR-19-3061. pmid: 31964785
[21]	国家食品药品监督管理局. 2022年03月18日药品批准证明文件待领取信息发布[EB/OL]. (2022-03-18)[2024-06-11]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220318112431186.html.
[22]	Umbralisib: treatment for a rare lymphoma?[J]. Cancer Discov, 2019, 9(6): OF5. DOI: 10.1158/2159-8290.CD-NB2019-045.
[23]	U.S. Food and Drug Administration. FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma[EB/OL]. (2021-02-05)[2024-06-11]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-umbralisib-marginal-zone-lymphoma-and-follicular-lymphoma.
[24]	Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma[J]. J Clin Oncol, 2021, 39(15): 1609-1618. DOI: 10.1200/JCO.20.03433.
[25]	Davids MS, O'Connor OA, Jurczak W, et al. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies[J]. Blood Adv, 2021, 5(23): 5332-5343. DOI: 10.1182/bloodadvances.2021005132. pmid: 34547767
[26]	国家食品药品监督管理局. 2022年11月14日药品批准证明文件送达信息发布[EB/OL]. (2022-11-14)[2024-06-11]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20221114091849119.html.
[27]	Wang T, Sun X, Qiu L, et al. The oral PI3kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: a phase Ⅱ, single-arm, open-label clinical trial[J]. Clin Cancer Resclassic, 2023, 29(8): 1440-1449. DOI: 10.1158/1078-0432.CCR-22-2939.
[28]	ClinicalTrials.gov. A phase 1, first-in-human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 319 in adult subjects with relapsed or refractory lymphoid malignancies[EB/OL]. (2011-02-11)[2024-06-11]. https://classic.clinicaltrials.gov/ct2/show/NCT01300026?term=AMG319&draw=2&rank=1.
[29]	ClinicalTrials.gov. A phase 3, randomized, open-label, controlled, multicenter study of zandelisib (ME-401) in combination with rituximab versus standard immunochemotherapy in patients with relapsed indolent non Hodgkin's lymphoma (iNHL)—The COASTAL Study[EB/OL]. (2021-08-13)[2024-06-11]. https://classic.clinicaltrials.gov/ct2/show/NCT04745832?term=Zandelisib&draw=2&rank=3.
[30]	ClinicalTrials.gov. A phase 2, open label study to assess the efficacy and safety of tenalisib (RP6530), a novel PI3K dual δ/γ inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)[EB/OL]. (2019-12-28) [2024-06-11]. https://classic.clinicaltrials.gov/ct2/show/NCT04204057?term=Tenalisib&draw=2&rank=2.
[31]	药物临床试验登记与信息公示平台. 一项评估ZX-101A治疗复发/难治性血液系统恶性肿瘤患者的Ⅰ/Ⅱ期研究[EB/OL]. (2021-12-29)[2024-06-11]. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.
[32]	ClinicalTrials.gov. A phase 1, open-label, dose escalation, safety and tolerability study of INCB040093 in subjects with previously treated B-cell malignancies[EB/OL]. (2013-06-30)[2024-06-11]. https://classic.clinicaltrials.gov/ct2/show/NCT01905813?cond=INCB-040093&draw=2&rank=1.
[33]	ClinicalTrials.gov. A phase 2, multicenter, open-label study of INCB050465, a PI3Kδ inhibitor in relapsed or refractory follicular lymphoma (CITADEL-203)[EB/OL]. (2017-04-24)[2024-06-11]. https://classic.clinicaltrials.gov/ct2/show/NCT03126019?term=Parsaclisib&draw=2&rank=3.
[34]	药物临床试验登记与信息公示平台. SHC014748M在惰性B细胞恶性血液肿瘤患者中的Ⅰ期临床研究[EB/OL]. (2018-07-02)[2024-06-11]. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.
[35]	ClinicalTrials.gov. First-in-human dose study of IOA-244 alone and in combination with pemetrexed/cisplatin in patients with advanced or metastatic cancers[EB/OL]. (2020-02-25)[2024-06-11]. https://classic.clinicaltrials.gov/ct2/show/NCT04328844?term=IOA-244&draw=2&rank=1.
[36]	药物临床试验登记与信息公示平台. TQ-B3525治疗滤泡性淋巴瘤临床试验[EB/OL]. (2023-04-11)[2024-06-11]. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.
[37]	药物临床试验登记与信息公示平台. HMPL-689治疗复发/难治边缘区淋巴瘤和滤泡性淋巴瘤的临床研究[EB/OL]. (2023-10-30)[2024-06-11]. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.
[38]	药物临床试验登记与信息公示平台. YY-20394在复发和/或难治性外周T/NK细胞淋巴瘤患者中的Ⅱ期临床实验[EB/OL]. (2021-11-29)[2024-06-11]. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.
[39]	药物临床试验登记与信息公示平台. 一项BGB-10188(一种磷脂酰肌醇3-激酶δ(PI3Kδ)抑制剂)联合泽布替尼治疗成熟B细胞恶性肿瘤患者以及联合替雷利珠单抗治疗实体瘤患者的剂量递增和扩展1/2期研究[EB/OL]. (2023-06-16)[2024-06-11]. http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml.
[40]	Vanhaesebroeck B, Perry MWD, Brown JR, et al. PI3K inhibitors are finally coming of age[J]. Nat Rev Drug Discov, 2021, 20(10): 741-769. DOI: 10.1038/s41573-021-00209-1. pmid: 34127844
[41]	Zhang Y, Ma Z, Wang Y, et al. Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis[J]. Expert Rev Clin Pharmacol, 2023, 16(9): 855-863. DOI: 10.1080/17512433.2023.2238602.
[42]	Hanlon A, Brander DM. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors[J]. Hematology Am Soc Hematol Educ Program, 2020(1): 346-356. DOI: 10.1182/hematology.2020000119. pmid: 33275709
[43]	中国抗癌协会血液肿瘤专业委员会, 中国临床肿瘤学会淋巴瘤专家委员会. 林普利塞治疗淋巴瘤临床应用指导原则[J]. 白血病·淋巴瘤, 2023, 32(5): 257-263. DOI: 10.3760/cma.j.cn115356-20230325-00077.
[44]	Wagner-Johnston ND, Sharman J, Furman RR, et al. Idelalisib immune-related toxicity is associated with improved treatment response[J]. Leuk Lymphoma, 2021, 62(12): 2915-2920. DOI: 10.1080/10428194.2021.1948038.
[45]	Tarantelli C, Argnani L, Zinzani PL, et al. PI3Kδ inhibitors as immunomodulatory agents for the treatment of lymphoma patients[J]. Cancers (Basel), 2021, 13(21): 5535. DOI: 10.3390/cancers13215535.
[46]	Cuneo A, Barosi G, Danesi R, et al. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper[J]. Hematol Oncol, 2019, 37(1): 3-14. DOI: 10.1002/hon.2540. pmid: 30187496
[47]	Ramanathan RK, Von Hoff DD, Eskens F, et al. Phase Ⅰb trial of the PI3K inhibitor copanlisib combined with the allosteric MEK inhibitor refametinib in patients with advanced cancer[J]. Target Oncol, 2020, 15(2): 163-174. DOI: 10.1007/s11523-020-00714-0. pmid: 32314268
[48]	Jfri A, Meltzer R, Mostaghimi A, et al. Incidence of cutaneous adverse events with phosphoinositide 3-kinase inhibitors as adjuvant therapy in patients with cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2022, 8(11): 1635-1643. DOI: 10.1001/jamaoncol.2022.4327.
[49]	Wang C, Jia F, Zhang Y. Simultaneous determination of idelalisib and its metabolite GS-563117 in dog plasma by LC-MS/MS: application to a pharmacokinetic study[J]. Biomed Chromatogr, 2019, 33(5): e4511. DOI: 10.1002/bmc.4511.
[50]	Gadi D, Griffith A, Wang Z, et al. Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia[J]. Br J Haematol, 2022, 197(2): 207-211. DOI: 10.1111/bjh.18053.
[51]	Witkowska M, Majchrzak A, Robak P, et al. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia[J]. Expert Opin Drug Metab Toxicol, 2023, 19(9): 617-633. DOI: 10.1080/17425255.2023.2260305.
[52]	中国抗癌协会肿瘤内分泌专业委员会, 重庆市中西医结合学会肿瘤内分泌分会. 肿瘤相关性高血糖管理指南(2021年版)[J]. 中国癌症杂志, 2021, 31(7): 651-687. DOI: 10.19401/j.cnki.1007-3639.2021.07.013.
[53]	Dreyling M, Santoro A, Mollica L, et al. Patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study[J]. Am J Hematol, 2020, 95(4): 362-371. DOI: 10.1002/ajh.25711.